MiRNA Profiling Identifies Deregulated MiRNAs Associated with Osteosarcoma Development and Time to Metastasis in Two Large Cohorts

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2017 Nov 10

PMID 29120535

Citations 29

Authors

Gitte B Andersen

Alice Knudsen

Henrik Hager

Lise L Hansen

Jorg Tost

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is an aggressive bone tumor primarily affecting children and adolescents. The etiology of OS is not fully understood. Thus, there is a great need to obtain a better understanding of OS development and progression. Alterations in miRNA expression contribute to the required molecular alterations for neoplastic initiation and progression. This study is the first to investigate miRNA expression in OS in a large discovery and validation cohort comprising a total of 101 OS samples. We established the signature of altered miRNA expression in OS by profiling the expression level of 752 miRNAs in 23 OS samples using sensitive LNA-enhanced qPCR assays. The identified miRNA expression changes were correlated with gene expression in the same samples. Furthermore, miRNA expression changes were validated in a second independent cohort consisting of 78 OS samples. Analysis of 752 miRNAs in the discovery cohort led to the identification of 33 deregulated miRNAs in OS. Twenty-nine miRNAs were validated with statistical significance in the second cohort comprising 78 OS samples. miRNA/mRNA targets were determined, and 361 genes with an inverse expression of the target miRNA were identified. Both the miRNAs and the identified target genes were associated with multiple pathways related to cancer as well as bone cell biology, thereby correlating the deregulated miRNAs with OS tumorigenesis. An analysis of the prognostic value of the 29 miRNAs identified miR-221/miR-222 to be significantly associated with time to metastasis in both cohorts. This study contributes to a more profound understanding of OS tumorigenesis, by substantiating the importance of miRNA deregulation. We have identified and validated 29 deregulated miRNAs in the - to our knowledge - largest discovery and validation cohorts used so far for miRNA analyses in OS. Two of the miRNAs showed a promising potential as prognostic biomarkers for the aggressiveness of OS.

Citing Articles

Intelligent structure prediction and visualization analysis of non-coding RNA in osteosarcoma research.

Chen L, He L, Liu B, Zhou Y, Lv L, Wang Z Front Oncol. 2024; 14:1255061.

PMID: 38532928 PMC: 10964489. DOI: 10.3389/fonc.2024.1255061.

Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cells.

Zhang F, Hao Y, Yang N, Liu M, Luo Y, Zhang Y BMC Cancer. 2024; 24(1):198.

PMID: 38347435 PMC: 10863210. DOI: 10.1186/s12885-024-11951-1.

The role of mitochondria-related lncRNAs in characterizing the immune landscape and supervising the prognosis of osteosarcoma.

Zhang Y, Ru N, Xue Z, Gan W, Pan R, Wu Z J Bone Oncol. 2023; 43:100506.

PMID: 37868616 PMC: 10585401. DOI: 10.1016/j.jbo.2023.100506.

Circulating and extracellular vesicle-derived microRNAs as biomarkers in bone-related diseases.

Huber J, Longaker M, Quarto N Front Endocrinol (Lausanne). 2023; 14:1168898.

PMID: 37293498 PMC: 10244776. DOI: 10.3389/fendo.2023.1168898.

The AGMK1-9T7 cell model of neoplasia: Evolution of DNA copy-number aberrations and miRNA expression during transition from normal to metastatic cancer cells.

Lewis Jr A, Thomas R, Breen M, Peden K, Teferedegne B, Foseh G PLoS One. 2022; 17(10):e0275394.

PMID: 36279283 PMC: 9591059. DOI: 10.1371/journal.pone.0275394.

References

McCarville M . The child with bone pain: malignancies and mimickers. Cancer Imaging. 2009; 9 Spec No A:S115-21. PMC: 2797463. DOI: 10.1102/1470-7330.2009.9043. View

Wei Y, Yang J, Yi L, Wang Y, Dong Z, Liu Z . MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer. Sci Rep. 2014; 4:7546. PMC: 4269886. DOI: 10.1038/srep07546. View

Li B, Lu Y, Wang H, Han X, Mao J, Li J . RETRACTED: miR-221/222 enhance the tumorigenicity of human breast cancer stem cells via modulation of PTEN/Akt pathway. Biomed Pharmacother. 2016; 79:93-101. DOI: 10.1016/j.biopha.2016.01.045. View

Kansara M, Teng M, Smyth M, Thomas D . Translational biology of osteosarcoma. Nat Rev Cancer. 2014; 14(11):722-35. DOI: 10.1038/nrc3838. View

Jones K, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo G . miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012; 72(7):1865-77. PMC: 3328547. DOI: 10.1158/0008-5472.CAN-11-2663. View

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

Scott G, Goga A, Bhaumik D, Berger C, Sullivan C, Benz C . Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2006; 282(2):1479-86. DOI: 10.1074/jbc.M609383200. View

Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H . Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res. 2014; 6(4):391-401. PMC: 4113501. View

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

10.

Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo J . Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int. 2016; 2016:3631764. PMC: 4913005. DOI: 10.1155/2016/3631764. View

11.

Li H, Xie S, Liu M, Chen Z, Liu X, Wang L . The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol. 2014; 45(1):197-208. DOI: 10.3892/ijo.2014.2415. View

12.

Zhang J, Wang D, Xiong J, Chen L, Huang J . MicroRNA-33a-5p suppresses growth of osteosarcoma cells and is downregulated in human osteosarcoma. Oncol Lett. 2015; 10(4):2135-2141. PMC: 4579969. DOI: 10.3892/ol.2015.3503. View

13.

Bielack S, Kempf-Bielack B, Delling G, Exner G, Flege S, Helmke K . Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20(3):776-90. DOI: 10.1200/JCO.2002.20.3.776. View

14.

Lulla R, Costa F, Bischof J, Chou P, de F Bonaldo M, Vanin E . Identification of Differentially Expressed MicroRNAs in Osteosarcoma. Sarcoma. 2011; 2011:732690. PMC: 3140035. DOI: 10.1155/2011/732690. View

15.

Zhang J, Tu Q, Bonewald L, He X, Stein G, Lian J . Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J Bone Miner Res. 2011; 26(8):1953-63. PMC: 3810406. DOI: 10.1002/jbmr.377. View

16.

Sempere L, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V . Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 2004; 5(3):R13. PMC: 395763. DOI: 10.1186/gb-2004-5-3-r13. View

17.

Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H . MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics. 2009; 6(3):131-9. PMC: 2890246. View

18.

Mizuno Y, Yagi K, Tokuzawa Y, Kanesaki-Yatsuka Y, Suda T, Katagiri T . miR-125b inhibits osteoblastic differentiation by down-regulation of cell proliferation. Biochem Biophys Res Commun. 2008; 368(2):267-72. DOI: 10.1016/j.bbrc.2008.01.073. View

19.

Brennecke J, Stark A, Russell R, Cohen S . Principles of microRNA-target recognition. PLoS Biol. 2005; 3(3):e85. PMC: 1043860. DOI: 10.1371/journal.pbio.0030085. View

20.

Liu H, Kato Y, Erzinger S, Kiriakova G, Qian Y, Palmieri D . The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer. 2012; 12:583. PMC: 3526403. DOI: 10.1186/1471-2407-12-583. View